Cargando…

2430. Impact of USCAST Proposed Breakpoint Changes to Aminoglycosides, Cyclines, and Levofloxacin on Carbapenem-Resistant Enterobacteriaceae at a US Tertiary Referral Academic Medical Center

BACKGROUND: USCAST is one of many national committees that establish standards for testing and interpreting antimicrobial susceptibility. While working closely with EUCAST, USCAST has proposed updated breakpoints for the aminoglycosides, fluoroquinolones, and tigecycline and is discussing updated br...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kulengowski, Brandon, Ingling, Gretchen, Wilhite, Kristen E, Burgess, David S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255409/ http://dx.doi.org/10.1093/ofid/ofy210.2083

Ejemplares similares

Aminoglycoside Susceptibility Agreement between an Automated System and Broth Microdilution for Carbapenem-resistant Enterobacteriaceae
por: Kulengowski, Brandon, et al.
Publicado: (2017)

1534. Polymyxin Antimicrobial Susceptibility (AST) Testing and Breakpoints for P. aeruginosa, A. baumannii, and Enterobacteriaceae: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST)
por: Pogue, Jason M, et al.
Publicado: (2019)

Polymyxin B Etest Fails to Distinguish Carbapenem-resistant Enterobacteriaceae with Elevated Polymyxin B MICs
por: Kulengowski, Brandon, et al.
Publicado: (2017)

Evaluation of automated systems for aminoglycosides and fluoroquinolones susceptibility testing for Carbapenem-resistant Enterobacteriaceae
por: Zhao, Zhichang, et al.
Publicado: (2017)

In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii
por: Juhas, Mario, et al.
Publicado: (2019)

Observation of D$_{1}$(2430)$^{+}$ and D$_{2}^{*}$(2470) $^{+}$
por: Butler, F, et al.
Publicado: (1994)

2430: Leading diverse and emerging scientists to success (LEADS)
por: Rubio, Doris, et al.
Publicado: (2018)

2801. Antimicrobial Spectrum of Plazomicin and Other Aminoglycosides against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales When Applying New Breakpoints
por: Sader, Helio S, et al.
Publicado: (2023)

Clinical Outcomes of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Infections with Susceptibilities among Levofloxacin, Cefepime, and Carbapenems
por: Walker, Kristy J., et al.
Publicado: (2018)

Mortality Impact of CLSI Carbapenem Breakpoint Changes in Enterobacteriaceae Bloodstream Infections: a Patient-level Analysis of Published Data
por: O’Donnell, J Nicholas, et al.
Publicado: (2017)

359 Epidemiology of Carbapenem-Resistant Enterobacteriaceae (CRE) at an Academic Medical Center
por: Leiner, Charles, et al.
Publicado: (2014)

124. Impact of Levofloxacin MIC on Outcomes with Levofloxacin Step-down Therapy in Enterobacteriaceae Bloodstream Infections
por: White, Melissa, et al.
Publicado: (2019)

Epidemiological characteristics of carbapenem-resistant Enterobacteriaceae and carbapenem-resistant Acinetobacter baumannii in a tertiary referral hospital in Korea
por: Kang, Sollan, et al.
Publicado: (2022)

Effects of breakpoint changes on carbapenem susceptibility rates of Enterobacteriaceae: Results from the SENTRY Antimicrobial Surveillance Program, United States, 2008 to 2012
por: Rennie, Robert P, et al.
Publicado: (2014)

Clinical Impact of Revised Cefepime Breakpoint in Patients With Enterobacteriaceae Bacteremia
por: Foong, Kap Sum, et al.
Publicado: (2019)

Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan
por: Wang, Jann-Tay, et al.
Publicado: (2015)

Resistance Pattern of Carbapenem on Enterobacteriaceae
por: Pokharel, Khilasa, et al.
Publicado: (2018)

1278. Impact of Different Breakpoint Criteria on the Susceptibility Rates of Enterobacterales resistant Subsets to the Aminoglycosides
por: Sader, Helio S, et al.
Publicado: (2020)

Prevalence and Characterization of Carbapenem-Resistant Enterobacteriaceae Isolated from Mulago National Referral Hospital, Uganda
por: Okoche, Deogratius, et al.
Publicado: (2015)

Combination Therapy with Aminoglycoside in Bacteremiasdue to ESBL-Producing Enterobacteriaceae in ICU
por: Benetazzo, Lucie, et al.
Publicado: (2020)

Difference in Susceptibility Between Carbapenemase- and Non–Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae
por: Clark, Justin, et al.
Publicado: (2021)

2430. Comorbidity and Severity of Illness Risk Adjustment for Hospital-Onset Clostridioides difficile Infection
por: Cabral, Stephanie, et al.
Publicado: (2019)

2416. Risk Factors and Outcomes of Bacteremia Caused by Carbapenem-Resistant Enterobacteriaceae Compared With Carbapenem Susceptible Enterobacteriaceae
por: Mahmood, Syed Faisal
Publicado: (2018)

Vital Signs: Carbapenem-Resistant Enterobacteriaceae
por: Jacob, Jesse T., et al.
Publicado: (2013)

1549. Impact of New Fluoroquinolone Breakpoints on Enterobacteriaceae Susceptibility Rates and Clinical Outcomes
por: Pettit, Natasha N, et al.
Publicado: (2019)

Clinical Impact of Revised Ciprofloxacin Breakpoint in Patients with Urinary Tract Infections by Enterobacteriaceae
por: Park, Ga Eun, et al.
Publicado: (2021)

Draft Genome Sequence of Amycolatopsis lurida NRRL 2430, Producer of the Glycopeptide Family Antibiotic Ristocetin
por: Kwun, Min Jung, et al.
Publicado: (2014)

642. Facility Reported vs. CLSI MIC Breakpoint Comparison of Carbapenem Non-susceptible (Carb-NS) Enterobacteriaceae (ENT) from 2016-2019: A Multicenter Evaluation
por: Gupta, Vikas, et al.
Publicado: (2021)

Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections
por: Falagas, Matthew E., et al.
Publicado: (2014)

Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections
por: Morrill, Haley J., et al.
Publicado: (2015)

Factors associated with acquisition of carbapenem-resistant Enterobacteriaceae
por: Lavagnoli, Lilian Silva, et al.
Publicado: (2017)

369 Outcomes of Patients with Carbapenem-Resistant Enterobacteriaceae
por: Raybould, Jillian, et al.
Publicado: (2014)

Carbapenem-Resistant Enterobacteriaceae Infections: Taiwan Aspects
por: Jean, Shio-Shin, et al.
Publicado: (2018)

Emerging superbugs: The threat of Carbapenem Resistant Enterobacteriaceae
por: Dong, Le Thanh, et al.
Publicado: (2020)

Evaluation of Resistance Mechanisms in Carbapenem-Resistant Enterobacteriaceae
por: Alizadeh, Naser, et al.
Publicado: (2020)

Intestinal Dysbiosis in Carriers of Carbapenem-Resistant Enterobacteriaceae
por: Korach-Rechtman, Hila, et al.
Publicado: (2020)

Antibiotic Susceptibility Patterns for Carbapenem-Resistant Enterobacteriaceae
por: Armin, Shahnaz, et al.
Publicado: (2023)

Impact of the Recent Clinical and Laboratory Standards Institute Breakpoint Changes on the Antimicrobial Spectrum of Aminoglycosides and the Activity of Plazomicin Against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales From United States Medical Centers
por: Sader, Helio S, et al.
Publicado: (2023)

1193. Comparison of the Clinical Outcomes of Patients With IMP-Type Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenem-Sensitive Enterobacteriaceae in Japan
por: Saito, Sho, et al.
Publicado: (2018)

Carbapenem-Resistant Enterobacteriaceae: A Retrospective Review of Presentation, Treatment, and Clinical Outcomes in a Tertiary Care Referral Hospital
por: Al Khamis, Mohammed, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rt65g7b291a3bm54tmu6hca1i3